Farnesyl pyrophosphate
Based on 1 publication(s) in Google Scholar
Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 372-97-4
- Formule: C15H28O7P2
- Masse moléculaire:382.33
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Farnesyl pyrophosphate
MoreVoir tous les produits spécifiques à Isoform Endogenous Metabolite
MoreVoir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
Description
In Vitro
Farnesyl pyrophosphate (0-120 μg/mL, 0-60 min) induces cell death in P815 cell, A20 cells, Jurkat T cells, spleen cells, thymocytes and neure[1].
Farnesyl pyrophosphate (0-60 μM, 0-60 min) activates TRPM2 opening for Ca2+ influx in P815 cells[1].
Farnesyl pyrophosphate (10 μM, 14-26 h) significantly reverses the cytotoxicity, ROS elevation and AKT phosphorylation caused by Simvastatin (HY-17502) in CT26 cells[2].
Farnesyl pyrophosphate (10 μM, 48 h) significantly reverses the inhibitory effect of Simvastatin on the production of cytokines in mouse intestinal intraepithelial lymphocytes (IELs)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Middle cerebral artery occlusion (MCAO) model established in adult C57BL/6J mice (male, 10 to 12 weeks old, weight: 22 to 26 g)[1]
-
Dosage:30 mg/mL, 3 μL
-
Administration:Injected into the left striatum, single dose
-
Result:Induced acute neuron death.
Induced TRPM2-mediated cell death axis.
Chemical Information
-
CAS No. 372-97-4
-
Masse moléculaire 382.33
-
Formule C15H28O7P2
-
SMILES
O=P(O)(O)OP(OC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)(O)=O
-
Synonyms
Farnesyl diphosphate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Dev Cell
2026 Apr 29:S1534-5807(26)00150-4. PMID: 42061405
Pureté et documentation
-
Fiche technique (267 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jing Chen, et al. Farnesyl pyrophosphate is a new danger signal inducing acute cell death. PLoS Biol. 2021 Apr 26;19(4):e3001134. [Content Brief]
[2]. Qi XF, et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett. 2010 Dec 15;199(3):277-87. [Content Brief]
[3]. Zhang J, et al. Statins directly suppress cytokine production in murine intraepithelial lymphocytes. Cytokine. 2013 Feb;61(2):540-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)